Navigation Links
Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
Date:9/1/2009

ical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. Fo
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
3. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
6. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
7. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
8. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
9. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Aileron Therapeutics, Inc. - Product Pipeline ... Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline Review ... Therapeutics, Inc.,s pharmaceutical research and development focus. ... therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, complete ... by drug target, mechanism of action (MoA), route ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... to thwart tumor,s comeback , , WEDNESDAY, Jan. 21 ... cancer stem cells or "tumor-initiating cells" which, when targeted ... malignant. , The finding bolsters the theory that cancer ... are resistant to conventional therapies and responsible for tumor ...
... January 2009 - A new study conducted at the ... the University of Bologna, and published by Elsevier in ... http://www.elsevier.com/locate/cortex ) shows that, in confabulating patients, memory accuracy ... cognitive processes supporting adaptive behavior need attentional resources for ...
... Technical University of Catalonia (UPC) and Universitat Autnoma de ... (ESA) to design and carry out a scientific experiment ... between drugs and cells differ under these conditions. The ... Vaquer, with a doctorate in Medicine from UAB, and ...
... Erdman, A Cogdell,Spencer Company, a subsidiary of Cogdell ... broke ground earlier this week on two new medical ... , The two projects, a ... Jackson, Tennessee and a $1.75 million cancer center in,Mebane, ...
... 21 Amil,Participacoes S.A. (Bovespa: AMIL3) ("Amilpar"), informs its ... a meeting held today, approved the,payment of Interest on ... per,common share, corresponding to the total amount of R$ ... 2009, based on shareholders, position of,January 21, 2009. , ...
... & Friends Stage Show Kicks-off This Month Helping ... Raise Funds for Research. Autism Speaks, the ... yearlong partnership with Thomas & FriendsTM Live! On ... musical stage show produced by AEG ThemeSTAR and ...
Cached Medicine News:Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 2Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 3Health News:When less attention improves behavior 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 3Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 3Health News:Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 3Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 4Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 5
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: